Velcade (bortezomib) is an anti-cancer drug treatment administered by IV. It is indicated for the treatment of two diseases: multiple myeloma and mantle cell lymphoma. It was first approved by the US Food & Drug Administration in 2003. In this entry we're citing the most commonly reported side effects of Velcade along with side effects of Velcade considered serious enough that they demand medical attention.
The following side effects are considered to be common side effects of taking Velcade. This shouldn't be taken to mean that every person receiving the treatment will experience any or all of these side effects. Some will experience none; others, perhaps more than their share.
The following serious side effects might occur as a result of receiving Velcade. If they do, one should seek immediate medical attention: